February 27, 2024
Minerva’s Roluperidone for Schizophrenia Symptoms Denied Approval by FDA
United States Food and Drug Administration, MFSD1 gene, Symptoms aspect, Schizophrenia, New Drug Application
New York Attorney General Demands Enhanced Safety Labeling for Pediatric Use of Singulair
Singulair, United States Food and Drug Administration, Pediatric brand name, Child, Lawyer (occupation)
Minerva Entangles in Web of FDA Rejection Again Over Schizophrenia Drug Roluperidone
United States Food and Drug Administration, MFSD1 gene, Schizophrenia
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Janux Shares Surge Over 200% on Promising Early Signs of PSA Response in Prostate Cancer Treatment
Prostate-Specific Antigen, Janux, JANX007, Malignant neoplasm of prostate